Does the media refer more to SNDX or CGON?

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 6 articles in the media. CG Oncology's average media sentiment score of 1.35 beat Syndax Pharmaceuticals' score of 0.99 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or SNDX?

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Mirum Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.99 beat Mirum Pharmaceuticals' score of 0.42 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TVTX or SNDX?

In the previous week, Travere Therapeutics had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 9 mentions for Travere Therapeutics and 6 mentions for Syndax Pharmaceuticals. Travere Therapeutics' average media sentiment score of 1.20 beat Syndax Pharmaceuticals' score of 0.99 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORKA or SNDX?

In the previous week, Oruka Therapeutics had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Oruka Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.99 beat Oruka Therapeutics' score of -0.07 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Syndax Pharmaceuticals (SNDX) Competitors

$18.18 -0.64 (-3.40%)

As of 09/11/2026 04:00 PM Eastern

Compare

SNDX vs. CGON, MIRM, TVTX, ORKA, and KNSA

Should you buy Syndax Pharmaceuticals stock or one of its competitors? Syndax Pharmaceuticals's main competitors and comparable companies include CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), Oruka Therapeutics (ORKA), and Kiniksa Pharmaceuticals International (KNSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Syndax Pharmaceuticals compare to CG Oncology?

Syndax Pharmaceuticals (NASDAQ:SNDX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Syndax Pharmaceuticals presently has a consensus price target of $42.30, suggesting a potential upside of 132.67%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 21.32%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Syndax Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Syndax Pharmaceuticals has a net margin of -87.52% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
CG Oncology	-3,602.68%	-25.20%	-23.98%

CG Oncology has lower revenue, but higher earnings than Syndax Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.35	-$285.42M	-$2.51	N/A
CG Oncology	$4.04M	1,587.40	-$160.99M	-$2.69	N/A

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 6 articles in the media. CG Oncology's average media sentiment score of 1.35 beat Syndax Pharmaceuticals' score of 0.99 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Syndax Pharmaceuticals beats CG Oncology on 8 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Syndax Pharmaceuticals has a net margin of -87.52% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Mirum Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Mirum Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.99 beat Mirum Pharmaceuticals' score of 0.42 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals currently has a consensus price target of $137.31, indicating a potential upside of 39.80%. Syndax Pharmaceuticals has a consensus price target of $42.30, indicating a potential upside of 132.67%. Given Syndax Pharmaceuticals' higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Mirum Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.23	-$23.36M	-$14.55	N/A
Syndax Pharmaceuticals	$172.35M	9.35	-$285.42M	-$2.51	N/A

Summary

Mirum Pharmaceuticals beats Syndax Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Travere Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Travere Therapeutics has a net margin of -7.35% compared to Syndax Pharmaceuticals' net margin of -87.52%. Travere Therapeutics' return on equity of -55.15% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

In the previous week, Travere Therapeutics had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 9 mentions for Travere Therapeutics and 6 mentions for Syndax Pharmaceuticals. Travere Therapeutics' average media sentiment score of 1.20 beat Syndax Pharmaceuticals' score of 0.99 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Travere Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	12.71	-$25.55M	-$0.46	N/A
Syndax Pharmaceuticals	$172.35M	9.35	-$285.42M	-$2.51	N/A

Travere Therapeutics currently has a consensus price target of $68.00, indicating a potential upside of 2.77%. Syndax Pharmaceuticals has a consensus price target of $42.30, indicating a potential upside of 132.67%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Travere Therapeutics beats Syndax Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Oruka Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Syndax Pharmaceuticals	$172.35M	9.35	-$285.42M	-$2.51	N/A

In the previous week, Oruka Therapeutics had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Oruka Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.99 beat Oruka Therapeutics' score of -0.07 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Oruka Therapeutics' return on equity of -21.65% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Oruka Therapeutics presently has a consensus target price of $133.00, indicating a potential upside of 43.97%. Syndax Pharmaceuticals has a consensus target price of $42.30, indicating a potential upside of 132.67%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Oruka Therapeutics beats Syndax Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Syndax Pharmaceuticals currently has a consensus target price of $42.30, suggesting a potential upside of 132.67%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 14.56%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Syndax Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.35	-$285.42M	-$2.51	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.78	$59.01M	$0.97	78.63

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.35 beat Syndax Pharmaceuticals' score of 0.99 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Syndax Pharmaceuticals' net margin of -87.52%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Summary

Kiniksa Pharmaceuticals International beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.61B	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-7.24	14.18	274.94	25.33
Price / Sales	9.35	1,375.01	685.45	111.12
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	24.57	15.12	10.33	6.20
Net Income	-$285.42M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-11.58%	-4.34%	-3.32%	-2.35%
1 Month Performance	-4.72%	0.54%	-0.53%	-3.23%
1 Year Performance	16.91%	40.74%	23.51%	8.79%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	3.6249 of 5 stars	$18.18 -3.4%	$42.30 +132.7%	+16.9%	$1.61B	$172.35M	N/A	298	News Coverage
CGON CG Oncology	3.1647 of 5 stars	$72.35 +0.5%	$87.78 +21.3%	+117.0%	$6.41B	$4.04M	N/A	142	Positive News Options Volume
MIRM Mirum Pharmaceuticals	2.7522 of 5 stars	$98.22 -2.4%	$137.31 +39.8%	+32.2%	$6.38B	$521.31M	N/A	433	Positive News
TVTX Travere Therapeutics	1.6818 of 5 stars	$66.17 -2.0%	$64.09 -3.1%	+181.9%	$6.24B	$490.73M	N/A	497	Positive News Insider Trade
ORKA Oruka Therapeutics	3.3551 of 5 stars	$92.38 +0.8%	$133.00 +44.0%	+499.9%	$6.12B	N/A	N/A	68

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. CGON, MIRM, TVTX, ORKA, and KNSA

How does Syndax Pharmaceuticals compare to CG Oncology?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to Travere Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Oruka Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. CGON, MIRM, TVTX, ORKA, and KNSA

How does Syndax Pharmaceuticals compare to CG Oncology?

Do analysts recommend SNDX or CGON?

Do insiders and institutionals hold more shares of SNDX or CGON?

Which has more risk and volatility, SNDX or CGON?

Is SNDX or CGON more profitable?

Which has higher earnings & valuation, SNDX or CGON?

Does the media refer more to SNDX or CGON?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Is MIRM or SNDX more profitable?

Which has more volatility and risk, MIRM or SNDX?

Does the media prefer MIRM or SNDX?

Do analysts rate MIRM or SNDX?

Which has better valuation & earnings, MIRM or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Travere Therapeutics?

Which has more risk & volatility, TVTX or SNDX?

Is TVTX or SNDX more profitable?

Does the media refer more to TVTX or SNDX?

Which has stronger valuation and earnings, TVTX or SNDX?

Do analysts rate TVTX or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Oruka Therapeutics?

Which has more volatility & risk, ORKA or SNDX?

Which has preferable valuation and earnings, ORKA or SNDX?

Does the media favor ORKA or SNDX?

Is ORKA or SNDX more profitable?

Do analysts rate ORKA or SNDX?

Do institutionals and insiders believe in ORKA or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Do analysts rate SNDX or KNSA?

Do insiders and institutionals have more ownership in SNDX or KNSA?

Which has more risk & volatility, SNDX or KNSA?

Which has higher earnings and valuation, SNDX or KNSA?

Does the media favor SNDX or KNSA?

Is SNDX or KNSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools